Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1795, Issue 2, 2009, Pages 92-103

  van Staveren, W C G ^a   Solís, D Y Weiss ^a   Hebrant A ^a   Detours, V ^a   Dumont, J E ^a   Maenhaut, C ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cancer stem cell; Evolution; Human cancer cell line; Oncogene addiction; Opportunities; Pitfall

Indexed keywords

CANCER CELL CULTURE; CANCER MODEL; CANCER STEM CELL; EPIGENETICS; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW;

CELL LINE, TUMOR; EVOLUTION; HUMANS; NEOPLASTIC STEM CELLS; ONCOGENES; PHENOTYPE;

EID: 62749153738     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2008.12.004     Document Type: Review

References (120)

1. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A.L., Klijn J.G., Foekens J.A., Cardoso F., Piccart M.J., Buyse M., and Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13 (2007) 3207-3214
2. Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.K., Protopopov A., O'Neil J., Gutierrez A., Ivanova E., Perna I., Lin E., Mani V., Jiang S., McNamara K., Zaghlul S., Edkins S., Stevens C., Brennan C., Martin E.S., Wiedemeyer R., Kabbarah O., Nogueira C., Histen G., Aster J., Mansour M., Duke V., Foroni L., Fielding A.K., Goldstone A.H., Rowe J.M., Wang Y.A., Look A.T., Stratton M.R., Chin L., Futreal P.A., and DePinho R.A. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447 (2007) 966-971
3. Vargo-Gogola T., and Rosen J.M. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer 7 (2007) 659-672
4. Rangarajan A., and Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3 (2003) 952-959
5. Burniat A., Jin L., Detours V., Driessens N., Goffard J.C., Santoro M., Rothstein J., Dumont J.E., Miot F., and Corvilain B. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology (2008) 5107-5117
6. Wang H., Mannava S., Grachtchouk V., Zhuang D., Soengas M.S., Gudkov A.V., Prochownik E.V., and Nikiforov M.A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27 (2008) 1905-1915
7. Yeung S.C., She M., Yang H., Pan J., Sun L., and Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92 (2007) 2902-2909
8. Masters J.R. Human cancer cell lines: fact and fantasy. Nat. Rev. Mol. Cell Biol. 1 (2000) 233-236
9. P. Hughes, D. Marshall, Y. Reid, H. Parkes, C. Gelber, The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?, Biotechniques 43 (2007) 575, 577-2.
10. Nelson-Rees W.A., Daniels D.W., and Flandermeyer R.R. Cross-contamination of cells in culture. Science 212 (1981) 446-452
11. Le Beyec J., Xu R., Lee S.Y., Nelson C.M., Rizki A., Alcaraz J., and Bissell M.J. Cell shape regulates global histone acetylation in human mammary epithelial cells. Exp. Cell Res. 313 (2007) 3066-3075
12. Harlin H., and Gajewski T.F. Diagnosis and treatment of mycoplasma-contaminated cell cultures. Curr. Protoc. Cytom. Appendix 3 (2008) Appendix
13. Rae J.M., Creighton C.J., Meck J.M., Haddad B.R., and Johnson M.D. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 104 (2007) 13-19
14. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L., Copland J.A., Smallridge R.C., and Haugen B.R. DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. (2008) 4331-4341
15. van Staveren W.C.G., Weiss Solis D., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., and Maenhaut C. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 67 (2007) 8113-8120
16. Ertel A., Verghese A., Byers S.W., Ochs M., and Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 5 (2006) 55
17. Dairkee S.H., Ji Y., Ben Y., Moore D.H., Meng Z., and Jeffrey S.S. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 5 (2004) 47
18. Stephens P., Edkins S., Davies H., Greenman C., Cox C., Hunter C., Bignell G., Teague J., Smith R., Stevens C., O'Meara S., Parker A., Tarpey P., Avis T., Barthorpe A., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B., Yuen S.T., Nicholson A.G., Lakhani S., Easton D.F., Weber B.L., Stratton M.R., Futreal P.A., and Wooster R. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37 (2005) 590-592
19. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., and Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9 (2006) 391-403
20. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., Chin L., and DePinho R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
21. Jarvinen A.K., Autio R., Haapa-Paananen S., Wolf M., Saarela M., Grenman R., Leivo I., Kallioniemi O., Makitie A.A., and Monni O. Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene 25 (2006) 6997-7008
22. Sandberg R., and Ernberg I. The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol. 6 (2005) R65
23. Sandberg R., and Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2052-2057
24. Muthusamy V., Duraisamy S., Bradbury C.M., Hobbs C., Curley D.P., Nelson B., and Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 66 (2006) 11187-11193
25. Sabatino M., Zhao Y., Voiculescu S., Monaco A., Robbins P., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., and Wang E. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 68 (2008) 122-131
26. Molnar V., Tamasi V., Bakos B., Wiener Z., and Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin. Cancer Biol. 18 (2008) 111-122
27. Heller G., Schmidt W.M., Ziegler B., Holzer S., Mullauer L., Bilban M., Zielinski C.C., Drach J., and Zochbauer-Muller S. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 68 (2008) 44-54
28. Schagdarsurengin U., Gimm O., Dralle H., Hoang-Vu C., and Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16 (2006) 633-642
29. Ehrich M., Turner J., Gibbs P., Lipton L., Giovanneti M., Cantor C., and van den B.D. Cytosine methylation profiling of cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4844-4849
30. Ross D.T., and Perou C.M. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis. Markers 17 (2001) 99-109
31. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de R.M., Waltham M., Pergamenschikov A., Lee J.C., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., and Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 (2000) 227-235
32. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., and Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006) 515-527
33. Zhu Y., Wang A., Liu M.C., Zwart A., Lee R.Y., Gallagher A., Wang Y., Miller W.R., Dixon J.M., and Clarke R. Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int. J. Oncol. 29 (2006) 1581-1589
34. Creighton C.J., Cordero K.E., Larios J.M., Miller R.S., Johnson M.D., Chinnaiyan A.M., Lippman M.E., and Rae J.M. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 7 (2006) R28
35. Gius D., Funk M.C., Chuang E.Y., Feng S., Huettner P.C., Nguyen L., Bradbury C.M., Mishra M., Gao S., Buttin B.M., Cohn D.E., Powell M.A., Horowitz N.S., Whitcomb B.P., and Rader J.S. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 67 (2007) 7113-7123
36. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adelaide J., Cervera N., Fekairi S., Xerri L., Jacquemier J., Birnbaum D., and Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25 (2006) 2273-2284
37. Saaf A.M., Halbleib J.M., Chen X., Yuen S.T., Leung S.Y., Nelson W.J., and Brown P.O. Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer. Mol. Biol. Cell 18 (2007) 4245-4260
38. Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., and Sobrinho-Simoes M. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 17 (2007) 707-715
39. Jones S., Chen W.D., Parmigiani G., Diehl F., Beerenwinkel N., Antal T., Traulsen A., Nowak M.A., Siegel C., Velculescu V.E., Kinzler K.W., Vogelstein B., Willis J., and Markowitz S.D. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4283-4288
40. Walker M.C., Parris C.N., and Masters J.R. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J. Natl. Cancer Inst. 79 (1987) 213-216
41. Merlo L.M., Pepper J.W., Reid B.J., and Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6 (2006) 924-935
42. Allred D.C., Wu Y., Mao S., Nagtegaal I.D., Lee S., Perou C.M., Mohsin S.K., O'Connell P., Tsimelzon A., and Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin. Cancer Res. 14 (2008) 370-378
43. Hill R.P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66 (2006) 1891-1895
44. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., Backlund M.G., Yin Y., Khramtsov A.I., Bastein R., Quackenbush J., Glazer R.I., Brown P.H., Green J.E., Kopelovich L., Furth P.A., Palazzo J.P., Olopade O.I., Bernard P.S., Churchill G.A., Van Dyke T., and Perou C.M. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8 (2007) R76
45. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., Rehm S., Russo J., Tavassoli F.A., Wakefield L.M., Ward J.M., and Green J.E. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 19 (2000) 968-988
46. Odom D.T., Dowell R.D., Jacobsen E.S., Gordon W., Danford T.W., MacIsaac K.D., Rolfe P.A., Conboy C.M., Gifford D.K., and Fraenkel E. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 39 (2007) 730-732
47. Hahn W.C., and Weinberg R.A. Rules for making human tumor cells. N. Engl. J. Med. 347 (2002) 1593-1603
48. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., Macleod M., Mignini L.E., Jayaram P., and Khan K.S. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334 (2007) 197
49. Campbell L.L., and Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 6 (2007) 2332-2338
50. Gieseg M.A., Man M.Z., Gorski N.A., Madore S.J., Kaldjian E.P., and Leopold W.R. The influence of tumor size and environment on gene expression in commonly used human tumor lines. BMC Cancer 4 (2004) 35
51. Ohta S., Lai E.W., Morris J.C., Pang A.L., Watanabe M., Yazawa H., Zhang R., Green J.E., Chan W.Y., Sirajuddin P., Taniguchi S., Powers J.F., Tischler A.S., and Pacak K. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Mol. Carcinog. 47 (2008) 245-251
52. Dumont J.E., Willems C., Van Sande J., and Neve P. Regulation of the release of thyroid hormones: role of cyclic AMP. Ann. N. Y. Acad. Sci. 185 (1971) 291-316
53. O'Hare M.J., Ormerod M.G., Monaghan P., Lane E.B., and Gusterson B.A. Characterization in vitro of luminal and myoepithelial cells isolated from the human mammary gland by cell sorting. Differentiation 46 (1991) 209-221
54. Martin M.J., Muotri A., Gage F., and Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 11 (2005) 228-232
55. Shay J.W., and Wright W.E. Tissue culture as a hostile environment: identifying conditions for breast cancer progression studies. Cancer Cell 12 (2007) 100-101
56. Ince T.A., Richardson A.L., Bell G.W., Saitoh M., Godar S., Karnoub A.E., Iglehart J.D., and Weinberg R.A. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12 (2007) 160-170
57. Simon M.C., and Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat. Rev. Mol. Cell Biol. 9 (2008) 285-296
58. Witt Hamer P.C., Van Tilborg A.A., Eijk P.P., Sminia P., Troost D., Van Noorden C.J., Ylstra B., and Leenstra S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27 (2008) 2091-2096
59. Jacks T., and Weinberg R.A. Taking the study of cancer cell survival to a new dimension. Cell 111 (2002) 923-925
60. Kenny P.A., Lee G.Y., and Bissell M.J. Targeting the tumor microenvironment. Front. Biosci. 12 (2007) 3468-3474
61. Yamada K.M., and Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 130 (2007) 601-610
62. Witz I.P. Yin-yang activities and vicious cycles in the tumor microenvironment. Cancer Res. 68 (2008) 9-13
63. Li H., Fan X., and Houghton J.M. Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell. Biochem. 6 (2006) 1-12
64. Brown M.F., Gratton T.P., and Stuart J.A. Metabolic rate does not scale with body mass in cultured mammalian cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R2115-R2121
65. Hébrant A., van Staveren W.C.G., Delys L., Weiss Solis D., Bogdanova T., Andry G., Roger P., Dumont J.E., Libert F., and Maenhaut C. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp. Cell Res. 313 (2007) 3276-3284
66. van Staveren W.C.G., Weiss Solis D., Delys L., Venet D., Cappello M., Andry G., Dumont J.E., Libert F., Detours V., and Maenhaut C. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 413-418
67. Coclet J., Lamy F., Rickaert F., Dumont J.E., and Roger P.P. Intermediate filaments in normal thyrocytes: modulation of vimentin expression in primary cultures. Mol. Cell. Endocrinol. 76 (1991) 135-148
68. Lester R.D., Jo M., Montel V., Takimoto S., and Gonias S.L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178 (2007) 425-436
69. Alajati A., Laib A.M., Weber H., Boos A.M., Bartol A., Ikenberg K., Korff T., Zentgraf H., Obodozie C., Graeser R., Christian S., Finkenzeller G., Stark G.B., Heroult M., and Augustin H.G. Spheroid-based engineering of a human vasculature in mice. Nat. Methods 5 (2008) 439-445
70. Chang H.Y., Chi J.T., Dudoit S., Bondre C., Van de R.M., Botstein D., and Brown P.O. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12877-12882
71. Camphausen K., Purow B., Sproull M., Scott T., Ozawa T., Deen D.F., and Tofilon P.J. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8287-8292
72. Nakamura T., Kuwai T., Kitadai Y., Sasaki T., Fan D., Coombes K.R., Kim S.J., and Fidler I.J. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res. 67 (2007) 7597-7604
73. Soeda A., Inagaki A., Oka N., Ikegame Y., Aoki H., Yoshimura S., Nakashima S., Kunisada T., and Iwama T. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J. Biol. Chem. 283 (2008) 10958-10966
74. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., and Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007) 557-563
75. Gatenby R.A., and Gillies R.J. A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8 (2008) 56-61
76. Olivotto M., and Dello S.P. Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 7 (2008) 176-187
77. Moreno E. Is cell competition relevant to cancer?. Nat. Rev. Cancer 8 (2008) 141-147
78. Rubin H. Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6215-6221
79. O'Driscoll L., Gammell P., McKiernan E., Ryan E., Jeppesen P.B., Rani S., and Clynes M. Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells. J. Endocrinol. 191 (2006) 665-676
80. Rhee H.W., Zhau H.E., Pathak S., Multani A.S., Pennanen S., Visakorpi T., and Chung L.W. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell. Dev. Biol. Anim. 37 (2001) 127-140
81. Lanari C., Luthy I., Lamb C.A., Fabris V., Pagano E., Helguero L.A., Sanjuan N., Merani S., and Molinolo A.A. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res. 61 (2001) 293-302
82. Fayet G., and Hovsepian S. Isolation of a normal human thyroid cell line: hormonal requirement for thyroglobulin regulation. Thyroid 12 (2002) 539-546
83. Wheatley D.N. Convergence of metabolic rate of cultured cells from animals of different sizes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R2113-R2114
84. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
85. Mahale A.M., Khan Z.A., Igarashi M., Nanjangud G.J., Qiao R.F., Yao S., Lee S.W., and Aaronson S.A. Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. Cancer Res. 68 (2008) 1417-1426
86. Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., Genua M., Vigneri R., and Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 (2006) 4463-4475
87. Gao C., Furge K., Koeman J., Dykema K., Su Y., Cutler M.L., Werts A., Haak P., and Vande Woude G.F. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8995-9000
88. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., and Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
89. Rizki A., Weaver V.M., Lee S.Y., Rozenberg G.I., Chin K., Myers C.A., Bascom J.L., Mott J.D., Semeiks J.R., Grate L.R., Mian I.S., Borowsky A.D., Jensen R.A., Idowu M.O., Chen F., Chen D.J., Petersen O.W., Gray J.W., and Bissell M.J. A human breast cell model of preinvasive to invasive transition. Cancer Res. 68 (2008) 1378-1387
90. Loeb L.A. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res. 72 (1998) 25-56
91. Loeb L.A., and Christians F.C. Multiple mutations in human cancers. Mutat. Res. 350 (1996) 279-286
92. Sniegowski P.D., Gerrish P.J., Johnson T., and Shaver A. The evolution of mutation rates: separating causes from consequences. Bioessays 22 (2000) 1057-1066
93. Gruenert D.C., and Cozens A.L. Inheritance of phenotype in mammalian cells. Am. J. Physiol. 260 (1991) L386-L394
94. Nguyen D.X., and Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8 (2007) 341-352
95. Tai K.Y., Shiah S.G., Shieh Y.S., Kao Y.R., Chi C.Y., Huang E., Lee H.S., Chang L.C., Yang P.C., and Wu C.W. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 26 (2007) 3989-3997
96. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
97. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4 (1999) 199-207
98. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W., Cordon-Cardo C., Yancopoulos G.D., and DePinho R.A. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999) 468-472
99. Sharma S.V., Gajowniczek P., Way I.P., Lee D.Y., Jiang J., Yuza Y., Classon M., Haber D.A., and Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10 (2006) 425-435
100. Liu D., Liu Z., Jiang D., Dackiw A.P., and Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J. Clin. Endocrinol. Metab. 92 (2007) 4686-4695
101. Ball D.W., Jin N., Rosen D.M., Dackiw A., Sidransky D., Xing M., and Nelkin B.D. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab. 92 (2007) 4712-4718
102. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
103. Lee Y.M., and Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 5 (2006) 2110-2114
104. Podsypanina K., Politi K., Beverly L.J., and Varmus H.E. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5242-5247
105. Lindemann R.K. Stroma-initiated hedgehog signaling takes center stage in B-cell lymphoma. Cancer Res. 68 (2008) 961-964
106. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., and De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15 (2008) 504-514
107. Vescovi A.L., Galli R., and Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 6 (2006) 425-436
108. Phillips T.M., McBride W.H., and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98 (2006) 1777-1785
109. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., and Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68 (2008) 3243-3250
110. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M.K., Sukumar S., Parker L.M., Anderson K.S., Harris L.N., Garber J.E., Richardson A.L., Schnitt S.J., Nikolsky Y., Gelman R.S., and Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 11 (2007) 259-273
111. Polyak K. Is breast tumor progression really linear?. Clin. Cancer Res. 14 (2008) 339-341
112. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
113. Ben Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., and Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008) 499-507
114. Postovit L.M., Margaryan N.V., Seftor E.A., Kirschmann D.A., Lipavsky A., Wheaton W.W., Abbott D.E., Seftor R.E., and Hendrix M.J. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4329-4334
115. Baumann M., Krause M., and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8 (2008) 545-554
116. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson Jr. J.A., Marks J.R., Dressman H.K., West M., and Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
117. Arena S., Isella C., Martini M., de Marco A., Medico E., and Bardelli A. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res. 67 (2007) 8468-8476
118. Sala E., Mologni L., Truffa S., Gaetano C., Bollag G.E., and Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6 (2008) 751-759
119. Omerovic J., Hammond D.E., Clague M.J., and Prior I.A. Ras isoform abundance and signalling in human cancer cell lines. Oncogene 27 (2008) 2754-2762
120. Reich M., Liefeld T., Gould J., Lerner J., Tamayo P., and Mesirov J.P. GenePattern 2.0. Nat. Genet. 38 (2006) 500-501